| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1040953212 |
| P356 | DOI | 10.1186/1471-2407-11-28 |
| P932 | PMC publication ID | 3033852 |
| P698 | PubMed publication ID | 21251271 |
| P5875 | ResearchGate publication ID | 49770908 |
| P50 | author | Hong Ding | Q51681008 |
| Xiao-Dong Zhu | Q83249510 | ||
| P2093 | author name string | Lu Wang | |
| Wei Zhang | |||
| Zhao-You Tang | |||
| Dong-Mei Gao | |||
| Hui-Chuan Sun | |||
| Wei-Zhong Wu | |||
| Ju-Bo Zhang | |||
| Ling-Qun Kong | |||
| Peng-Yuan Zhuang | |||
| Hua-Xiang Xu | |||
| Pei-Li Fan | |||
| Yu-Quan Xiong | |||
| P2860 | cites work | Global cancer statistics, 2002 | Q27860562 |
| Sorafenib in advanced hepatocellular carcinoma | Q27861075 | ||
| Management of hepatocellular carcinoma | Q29616230 | ||
| Clinical translation of angiogenesis inhibitors | Q34152769 | ||
| Quantification of blood flow | Q34344510 | ||
| Normalizing tumor vasculature with anti-angiogenic therapy: a new paradigm for combination therapy | Q34354300 | ||
| Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. | Q34579127 | ||
| Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity | Q34580980 | ||
| Diagnosis of hepatic nodules 20 mm or smaller in cirrhosis: Prospective validation of the noninvasive diagnostic criteria for hepatocellular carcinoma. | Q34585928 | ||
| Phase II trial evaluating the clinical and biologic effects of bevacizumab in unresectable hepatocellular carcinoma | Q34593345 | ||
| VEGF-targeted therapy: mechanisms of anti-tumour activity. | Q34791610 | ||
| The small-molecule VEGF receptor inhibitor pazopanib (GW786034B) targets both tumor and endothelial cells in multiple myeloma | Q35540030 | ||
| Angiogenesis in hepatocellular carcinoma: the retrospectives and perspectives | Q35701281 | ||
| Angiogenesis and hepatocellular carcinoma | Q35935624 | ||
| Systematic review: evidence-based management of hepatocellular carcinoma--an updated analysis of randomized controlled trials. | Q36476765 | ||
| Dynamic contrast-enhanced magnetic resonance imaging as an imaging biomarker | Q36531396 | ||
| New perspectives for the use of contrast-enhanced liver ultrasound in clinical practice. | Q36701684 | ||
| Development of sorafenib and other molecularly targeted agents in hepatocellular carcinoma | Q37015632 | ||
| From molecular biology to targeted therapies for hepatocellular carcinoma: the future is now. | Q37034876 | ||
| Contrast-enhanced ultrasound in the diagnosis of hepatocellular carcinoma. | Q37105121 | ||
| Biomarkers of angiogenesis for the development of antiangiogenic therapies in oncology: tools or decorations? | Q37193620 | ||
| Human hepatocellular carcinoma tumor-derived endothelial cells manifest increased angiogenesis capability and drug resistance compared with normal endothelial cells | Q39819720 | ||
| Dynamic assessment of antiangiogenic therapy by monitoring both tumoral vascularization and tissue degeneration | Q40237701 | ||
| Angiogenesis inhibitors in a murine neuroblastoma model: quantitative assessment of intratumoral blood flow with contrast-enhanced gray-scale US. | Q40263635 | ||
| Both antiangiogenesis- and angiogenesis-independent effects are responsible for hepatocellular carcinoma growth arrest by tyrosine kinase inhibitor PTK787/ZK222584. | Q40427748 | ||
| Stepwise metastatic human hepatocellular carcinoma cell model system with multiple metastatic potentials established through consecutive in vivo selection and studies on metastatic characteristics | Q40555471 | ||
| Hepatocellular carcinoma treated with chemoembolization: assessment with contrast-enhanced doppler ultrasonography | Q42479758 | ||
| Can pre-operative contrast-enhanced dynamic MR imaging for prostate cancer predict microvessel density in prostatectomy specimens? | Q42610381 | ||
| Angiogenesis: noninvasive quantitative assessment with contrast-enhanced functional US in murine model | Q46486160 | ||
| Early antiangiogenic activity of bevacizumab evaluated by computed tomography perfusion scan in patients with advanced hepatocellular carcinoma | Q46729867 | ||
| Blood flow changes in hepatocellular carcinoma after the administration of thalidomide assessed by reperfusion kinetics during microbubble infusion: preliminary results | Q46851565 | ||
| A multivessel model describing replenishment kinetics of ultrasound contrast agent for quantification of tissue perfusion | Q47406178 | ||
| Contrast agent specific imaging modes for the ultrasonic assessment of parenchymal cerebral echo contrast enhancement | Q49133130 | ||
| Dynamic CT Evaluation of Tumor Vascularity in Renal Cell Carcinoma. | Q53541487 | ||
| Sensitive noninvasive monitoring of tumor perfusion during antiangiogenic therapy by intermittent bolus-contrast power Doppler sonography | Q64025812 | ||
| Radiofrequency thermal ablation of hepatocellular carcinoma: using contrast-enhanced harmonic power doppler sonography to assess treatment outcome | Q74537092 | ||
| Hepatocellular carcinoma treatment with percutaneous ethanol injection: evaluation with contrast-enhanced color Doppler US | Q77528869 | ||
| Pimonidazole: a novel hypoxia marker for complementary study of tumor hypoxia and cell proliferation in cervical carcinoma | Q77593212 | ||
| Comparisons among pimonidazole binding, oxygen electrode measurements, and radiation response in C3H mouse tumors | Q77729027 | ||
| High expression of macrophage colony-stimulating factor in peritumoral liver tissue is associated with poor survival after curative resection of hepatocellular carcinoma | Q81351659 | ||
| Diagnosis of small hepatic nodules detected by surveillance ultrasound in patients with cirrhosis: Comparison between contrast-enhanced ultrasound and contrast-enhanced helical computed tomography | Q81379683 | ||
| Vessel fractions in tumor xenografts depicted by flow- or contrast-sensitive three-dimensional high-frequency Doppler ultrasound respond differently to antiangiogenic treatment | Q81895679 | ||
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | angiogenesis inhibitor | Q574834 |
| xenograft | Q64148587 | ||
| P304 | page(s) | 28 | |
| P577 | publication date | 2011-01-20 | |
| P1433 | published in | BMC Cancer | Q326300 |
| P1476 | title | Antiangiogenic effects of pazopanib in xenograft hepatocellular carcinoma models: evaluation by quantitative contrast-enhanced ultrasonography | |
| P478 | volume | 11 |
| Q39146399 | Antiangiogenic therapy promoted metastasis of hepatocellular carcinoma by suppressing host-derived interleukin-12b in mouse models. |
| Q53511049 | Effects of Pazopanib, Sunitinib, and Sorafenib, Anti-VEGF Agents, on the Growth of Experimental Endometriosis in Rats. |
| Q42053469 | Hepatocellular Carcinoma: Past and Future of Molecular Target Therapy |
| Q36198709 | Hepatocellular carcinoma treated with transarterial chemoembolization: Evaluation with parametric contrast-enhanced ultrasonography |
| Q92344153 | New Insight into Therapies Targeting Angiogenesis in Hepatocellular Carcinoma |
| Q39431960 | Novel EGFR-TK inhibitor EKB-569 inhibits hepatocellular carcinoma cell proliferation by AKT and MAPK pathways |
| Q38696525 | Overview of fundamental study of pazopanib in cancer |
| Q38354294 | Role of the fibroblast growth factor receptor axis in cholangiocarcinoma |
| Q53381128 | The multi-kinase inhibitor pazopanib targets hepatic stellate cell activation and apoptosis alleviating progression of liver fibrosis. |
| Q38805034 | Therapeutic application of anti-angiogenic nanomaterials in cancers |
Search more.